Comparative effectiveness and safety of oral anticoagulants for atrial fibrillation: A retrospective cohort study

Main Article Content

Anne Holbrook
Richard Morrow
Agnes Y. Y. Lee
Gary Foster
Eleanor Pullenyegum

Keywords

DOACs, Warfarin, Atrial Fibrillation, Cohort Study, Propensity score adjustment

Abstract

Oral anticoagulants (OACs) are high-priority medications, frequently used with clinically important benefit and serious harm. Our objective was to compare the safety and effectiveness of direct-acting oral anticoagulants (DOACs) versus warfarin in a population where anticoagulation management and DOACs were readily available. A retrospective cohort study of all adults living in British Columbia with a diagnosis of atrial fibrillation and a first prescription for an OAC was conducted. Co-primary outcomes were ischemic stroke and systemic embolism, and major bleeding. Secondary outcomes included a net clinical outcome composite and analysis of discontinuation, switching, and key subgroups. We estimated the effects of treatment using time-to-event models with high-dimen-sional propensity score adjustment to control confounding. After adjustment for prescribing bias, a cohort (n = 20,113, 43.8% female, mean age 72.4 years) with a mean follow-up of 18.1 months showed that patients taking warfarin tended to be poorer, sicker, and less likely to have a cardiologist prescriber. Outcome event rates were not significantly different for DOACs compared to warfarin [adjusted rate ratio of 1.15 (0.91, 1.46) for systemic embolism, 0.94 (0.82, 1.08) for major bleeding, and 0.98 (0.90, 1.06) for net clinical outcome]. Only the effect of age on net clinical outcome met our strict criteria for predicting which group might be superior. Switch of drug class was associ-ated with increased risk of events (p < 0.003). In this population, we found no difference in important clinical outcomes between warfarin and DOACs. Switching compared to not switch-ing was associated with harm.

Abstract 325 | PDF Downloads 122 HTML Downloads 21 XML Downloads 0

References

1. IOM (Institute of Medicine). Initial national priorities for comparative effectiveness research. The National Academies Press; 2009. Available at: http://www.nap.edu/openbook.php?record_id= 12648
2. Holbrook A, Dormuth C, Morrow R, et al. Comparative effectiveness and safety of oral anti-coagulants for atrial fibrillation in real-world practice: A population-based cohort study proto-col. BMJ Open 2016;6(11):e013263. https://doi. org/10.1136/bmjopen-2016-013263
3. Weitz JI, Semchuk W, Turpie AG, et al. Trends in  prescribing oral anticoagulants in Canada, 2008–2014. Clin Ther 2015;37(11):2506–14.e4. https://doi.org/10.1016/j.clinthera.2015.09.008
4. Institute for Safe Medication Practices (ISMP). Quarterwatch: Monitoring FDA Medwatch reports. Annual Report Issue. 2016. Available at: https://www.ismp.org/quarterwatch/pdfs/2015Q4. pdf
5. Canadian Institute for Health Information. Prescribed drug spending in Canada, 2018. Ottawa, ON: CIHI; 2018. Available at: https://secure.cihi. ca/free_products/pdex-report-2018-en-web.pdf
6. Chokshi DA, Avorn J, Kesselheim AS. Designing comparative effectiveness research on prescrip-tion drugs: Lessons from the clinical trial litera-ture. Health Aff (Millwood) 2010;29(10):1842–8. https://doi.org/10.1377/hlthaff.2010.0843
7. Eikelboom J, Parekh A, Pogue J, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361(12):1139–51. https://doi. org/10.1056/NEJMoa0905561
8. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365(10):883–91. https://doi.org/10.1056/NEJMoa1009638
9. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365(11):981–92. https://doi.org/10.1056/NEJMoa1107039
10. Wells G, Coyle D, Cameron C, et al. Safety, effectiveness, and cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2012.
11. Lutz J, Jurk K, Schinzel H. Direct oral anticoagu-lants in patients with chronic kidney disease: Patient selection and special considerations. Int J Nephrol Renovasc Dis 2017;10:135–43. https:// doi.org/10.2147/IJNRD.S105771
12. Castellucci LA, Shaw J, van der Salm K, et al. Self-reported adherence to anticoagulation and its determinants using the Morisky medication adherence scale. Thromb Res 2015;136(4):727–31. https://doi.org/10.1016/j.thromres.2015.07.007
13. Sarich TC, Seltzer JH, Berkowitz SD, et al. Novel  oral anticoagulants and reversal agents:  Considerations for clinical development. Am  Heart J 2015;169(6):751–7. https://doi.org/ 10.1016/j.ahj.2015.03.010
14. Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience. Prescrire Int 2013;22(139):155–9.
15. Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e152S–84S. https://doi.org/10.1378/chest.141.4.1129b
16. Gomez-Outes A, Terleira-Fernandez AI, Calvo-Rojas G, Suarez-Gea ML, Vargas-Castrillon E. Dabigatran, rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibril-lation: A systematic review and meta-analysis of  subgroups. Thrombosis 2013;2013:640723. https://doi.org/10.1155/2013/640723
17. Bruins Slot KM, Berge E. Factor Xa inhibitors versus vitamin K antagonists for preventing cere-bral or systemic embolism in patients with atrial  fibrillation. Cochrane Database Syst Rev 2018;3:CD008980. https://doi.org/10.1002/ 14651858.CD008980.pub2
18. Appelboam R, Thomas EO. Warfarin and intra-cranial haemorrhage. Blood Rev 2009;23(1):1–9. https://doi.org/10.1016/j.blre.2008.05.001
19. Mello MM, Goodman SN, Faden RR. Ethical considerations in studying drug safety—The Institute of Medicine report. N Engl J Med 2012;367(10):959–64. https://doi.org/10.1056/ NEJMhle1207160
20. D'Agostino Jr RB, D'Agostino SrRB . Estimating treatment effects using observational data. J Am Med Assoc 2007;297(3):314–16. https://doi.org/ 10.1001/jama.297.3.314
21. Dreyer N, Schneeweiss S, McNeil B, et al. GRACE principles: Recognizing high-quality observational studies of comparative effectiveness. Am J Manag Care 2010;16(6):467–71.
22. Austin PC, Laupacis A. A tutorial on methods to estimating clinically and policy-meaningful mea-sures of treatment effects in prospective observa-tional studies: A review. Int J Biostat 2011;7(1):6. https://doi.org/10.2202/1557-4679.1285
23. Maura G, Blotiere PO, Bouillon K, et al. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabig-atran or rivaroxaban versus vitamin K antagonists: A French nationwide propensity-matched cohort study. Circulation 2015;132(13):1252–60. https:// doi.org/10.1161/CIRCULATIONAHA.115. 015710
24. Lauffenburger JC, Farley JF, Gehi AK, Rhoney DH, Brookhart MA, Fang G. Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: A retrospective cohort study. J Am Heart Assoc 2015;4(4). https://doi.org/10.1161/JAHA.115. 001798
25. Larsen TB, Rasmussen LH, Gorst-Rasmussen A, Skjoth F, Lane DA, Lip GY. Dabigatran and war-farin for secondary prevention of stroke in atrial fibrillation patients: A nationwide cohort study. Am J Med 2014;127(12):1172–8.e5. https://doi. org/10.1016/j.amjmed.2014.07.023
26. Laliberte F, Cloutier M, Crivera C, et al. Effects of rivaroxaban versus warfarin on hospitalization days and other health care resource utilization in patients with nonvalvular atrial fibrillation: An observational study from a cohort of matched users. Clin Ther 2015;37(3):554–62. https://doi. org/10.1016/j.clinthera.2015.02.001
27. Abraham NS, Singh S, Alexander GC, et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarIn: Population based cohort study. BMJ 2015;350:h1857. https:// doi.org/10.1136/bmj.h1857
28. Larsen TB, Rasmussen LH, Gorst-Rasmussen A, et al. Myocardial ischemic events in “Real world” patients with atrial fibrillation treated with dabigatran or warfarin. Am J Med 2014;127(4):329–36.e4. https://doi.org/10.1016/j. amjmed.2013.12.005
29. Larsen TB, Gorst-Rasmussen A, Rasmussen LH, Skjoth F, Rosenzweig M, Lip GYH. Bleeding events among new starters and switchers to dabig-atran compared with warfarin in atrial fibrilla-tion. Am J Med 2014;127(7):650–6. https://doi. org/10.1016/j.amjmed.2014.01.031
30. An J, Niu F, Lang DT, et al. Stroke and bleeding risk associated with antithrombotic therapy for patients with nonvalvular atrial fibrillation in clin-ical practice. J Am Heart Assoc 2015;4(7). https:// doi.org/10.1161/JAHA.115.001921
31. Ho CW, Ho MH, Chan PH, et al. Ischemic stroke and intracranial hemorrhage with aspirin, dabiga-tran, and warfarIn: Impact of quality of anticoag-ulation control. Stroke 2015;46(1):23–30. https:// doi.org/10.1161/STROKEAHA.114.006476
32. Larsen TB, Skjoth F, Nielsen PB, Kjaeldgaard JN, Lip GY. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: Propensity weighted nationwide cohort study. BMJ 2016;353(lart032161):i3189. https://doi.org/ 10.1136/bmj.i3189
33. Li X, Keshishian A, Hamilton M, et al. Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach. PLoS One 2018;13(1):e0191722. https://doi.org/10.1371/ journal.pone.0191722
34. Yao X, Abraham NS, Sangaralingham LR, et al. Effectiveness and safety of dabigatran, rivarox-aban, and apixaban versus warfarin in nonvalvu-lar atrial fibrillation. J Am Heart Assoc 2016;5(6). https://doi.org/10.1161/JAHA.116.003725
35. Staerk L, Fosbol EL, Lip GYH, et al. Ischaemic and haemorrhagic stroke associated with non-vita-min K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: A nationwide cohort study. Eur Heart J 2017;38(12):907–15. https://doi.org/10.1093/eurheartj/ehw496
36. Palamaner Subash Shantha G, Bhave PD, Girotra S, et al. Sex-specific comparative effectiveness of oral anticoagulants in elderly patients with newly diagnosed atrial fibrillation. Circ Cardiovasc Qual Outcomes 2017;10(4). https://doi.org/10.1161/ CIRCOUTCOMES.116.003418
37. Hernandez I, Zhang Y, Brooks MM, Chin PK, Saba S. Anticoagulation use and clinical outcomes after major bleeding on dabigatran or warfarin in atrial fibrillation. Stroke 2017;48(1):159–66. https:// doi.org/10.1161/STROKEAHA.116.015150
38. Nielsen PB, Skjoth F, Sogaard M, Kjaeldgaard JN, Lip GY, Larsen TB. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anti-coagulants and warfarin in patients with atrial fibrillation: Propensity weighted nationwide cohort study. BMJ 2017;356:j510. https://doi.org/10.1136/ bmj.j510
39. Norby FL, Bengtson LGS, Lutsey PL, et al. Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation. BMC Cardiovasc Disord 2017;17(1):238. https://doi. org/10.1186/s12872-017-0672-5
40. Li WH, Huang D, Chiang CE, et al. Efficacy and safety of dabigatran, rivaroxaban, and warfarin for stroke prevention in Chinese patients with atrial fibrillation: The Hong Kong Atrial Fibrillation Project. Clin Cardiol 2017;40(4):222–9. https://doi. org/10.1002/clc.22649
41. Lip GY, Pan X, Kamble S, et al. Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: A “real-world” observational study in the United States. Int J Clin Pract 2016;70(9): 752–63. https://doi.org/10.1111/ijcp.12863
42. Lip GY, Keshishian A, Kamble S, et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfa-rin. A propensity score matched analysis. Thromb Haemost 2016;116(5):975–86. https://doi.org/ 10.1160/TH16-05-0403
43. Chan YH, Yen KC, See LC, et al. Cardiovascular, bleeding, and mortality risks of dabigatran in Asians with nonvalvular atrial fibrillation. Stroke  2016;47(2):441–9. https://doi.org/10.1161/ STROKEAHA.115.011476
44. Chan PH, Huang D, Hai JJ, et al. Stroke preven-tion using dabigatran in elderly Chinese patients with atrial fibrillation. Heart Rhythm 2016;13(2): 366–73. https://doi.org/10.1016/j.hrthm.2015. 09.015
45. Avgil-Tsadok M, Jackevicius CA, Essebag V, et al. Dabigatran use in elderly patients with atrial fibril-lation. Thromb Haemost 2016;115(1):152–60. https://doi.org/10.1160/TH15-03-0247
46. Avgil Tsadok M, Jackevicius CA, Rahme E, Humphries KH, Pilote L. Sex differences in dabigatran use, safety, and effectiveness in a population-based cohort of patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2015;8(6):593–9. https://doi.org/10.1161/ CIRCOUTCOMES.114.001398
47. Farr AM, Jing Y, Johnston S, et al. Comparison of hospital length of stay between hospitalized non-valvular atrial fibrillation patients treated with either apixaban or warfarin. Hosp Pract (1995) 2015;43(3):172–9. https://doi.org/10.1080/ 21548331.2015.1071635
48. Von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. Int J Surg 2014;12(12):1495–9. https://doi.org/10. 1016/j.ijsu.2014.07.013
49. British Columbia Ministry of Health [creator] (2011). Medical services plan (MSP) payment information file. V2. Population Data BC [pub-lisher]. Data Extract. MOH; 2018. Available at: http://www.popdata.bc.ca/data
50. BC Ministry of Health [creator] (2011). PharmaNet. V2. BC Ministry of Health [publisher]. Data Extract. Data Stewardship Committee; 2018. Available at: http://www.popdata.bc.ca/data
51. BC Vital Statistics Agency [creator] (2011). Vital statistics deaths. V2. Population Data BC [pub-lisher]. Data Extract BC Vital Statistics Agency; 2018. Available at: http://www.popdata.bc.ca/ data
52. Canadian Institute for Health Information [creator] (2011). Discharge abstract database (Hospital Separations). V2. Population Data BC [publisher]. Data Extract. MOH; 2018. Available at: http://www.popdata.bc.ca/data
53. BC Ministry of Health [creator] (2011). LifeLabs. BC Ministry of Health [publisher]. Data Extract. LifeLabs Medical Director; 2012. Available at: http://www.popdata.bc.ca/data
54. Varadhan R, Weiss CO, Segal JB, Wu AW, Scharfstein D, Boyd C. Evaluating health out-comes in the presence of competing risks: A review of statistical methods and clinical applications. Med Care 2010;48(6 Suppl):S96–105. https://doi. org/10.1097/MLR.0b013e3181d99107
55. Arnason T, Wells PS, van Walraven C, Forster AJ. Accuracy of coding for possible warfarin compli-cations in hospital discharge abstracts. Thromb Res 2006;118(2):253–62. https://doi.org/10.1016/j. thromres.2005.06.015
56. Juurlink D, Preyra C, Croxford R, et al. ICES investigative report-Canadian Institute for Health Information Discharge Abstract Database: A val-idation study. Institute for Clinical Evaluative Sciences (ICES); 2006. Available at: https://www. ices.on.ca/flip-publication/canadian-isti-tute-for-health-information-discharge/files/assets/ basic-html/index.html#1
57. Levy AR, O'Brien BJ, Sellors C, Grootendorst P, Willison D. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol 2003;10(2):67–71.
58. Quan H, Li B, Saunders LD, et al. Assessing valid-ity of ICD-9-CM and ICD-10 administrative data in recording clinical conditions in a unique dually coded database. Health Serv Res 2008;43(4): 1424–41. https://doi.org/10.1111/j.1475-6773.2007. 00822.x
59. Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 2009;20(4):
512–22. https://doi.org/ 10.1097/EDE.0b013e 3181a 663cc
60. Dormuth CR, Filion KB, Paterson JM, et al. Higher potency statins and the risk of new diabe-tes: Multicentre, observational study of adminis-trative databases. BMJ 2014;348:g3244. https:// doi.org/10.1136/bmj.g3244
61. Rothman KJ, Greenland S, Lash TL, editors. Design strategies to improve study accuracy. Modern epidemiology. 3rd ed. Lippincott Williams & Wilkins. 2008.
62. Hernan MA, Hernandez-Diaz S. Beyond the intention-to-treat in comparative effectiveness research. Clin Trials 2012;9(1):48–55. https://doi. org/10.1177/1740774511420743
63. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369(22):2093–104. https://doi.org/10.1056/NEJMoa1310907
64. Sterne JA, Bodalia PN, Bryden PA, et al. Oral anticoagulants for primary prevention, treat-ment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: Systematic review, network meta-analysis and cost-effectiveness analysis. Health Technol Assess (Winchester, England) 2017;21(9):1–386. https://doi.org/10. 3310/hta21090
65. Saber SS, Alipour S, Starovoytov A, MacGillivray J, Ramanathan K. 067 Quality of anticoagulation in community practices of British Columbia. Can J Cardiol 2012;28(5):S111. https://doi.org/10.1016/j. cjca.2012.07.078

Most read articles by the same author(s)